Inhaled corticosteroids in obstructive airway disease.

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Obstructive airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), are characterized by airway inflammation.
• Inhaled corticosteroids (ICS) are a cornerstone therapy for managing these inflammatory conditions.

Purpose of the Study:

• To review the role and efficacy of inhaled corticosteroids in managing asthma and COPD.
• To discuss the clinical evidence, benefits, and adverse effects of ICS in these patient populations.

Main Methods:

• Review of clinical evidence and guidelines regarding ICS use in asthma and COPD.
• Analysis of the impact of ICS on lung function, exacerbations, hospitalizations, and symptoms.
• Consideration of the safety profile and adverse effects associated with ICS therapy.

Main Results:

• Strong evidence supports ICS in all severities of persistent asthma for improved lung function, reduced exacerbations, and mortality prevention.
• In COPD patients with moderate-to-severe airflow limitation and persistent symptoms, ICS improve symptoms and reduce exacerbations and hospitalizations.
• Adverse effects of ICS are less common than systemic corticosteroids but warrant attention.

Conclusions:

• Inhaled corticosteroids are crucial for effective management of asthma and COPD.
• ICS should be considered in specific COPD patient groups despite potential adverse effects.
• Ongoing development aims to improve the properties and safety of future inhaled corticosteroid medications.